Repositioning Candidate Details
| Candidate ID: | R1411 |
| Source ID: | DB11830 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Mocetinostat |
| Synonyms: | Mocetinostat |
| Molecular Formula: | C23H20N6O |
| SMILES: | NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1 |
| Structure: |
|
| DrugBank Description: | Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others. |
| CAS Number: | 726169-73-9 |
| Molecular Weight: | 396.454 |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | All HDAC inhibitors induce histone H3 hyperacetylation, correlating with inhibition of proliferation, induction of cell differentiation and apoptosis. |
| DrugBank MoA: | Mocetinostat is a novel isotypic-selective inhibitor of the enzyme histone deacetylase (HDAC). HDAC inhibitors act by turning on tumour suppressor genes that have been inappropriately turned off. Tumour suppressor genes are a natural defense against cancer. It is therefore hypothesized that specifically inhibiting those HDACs involved in cancer with Mocetinostat may restore normal cell function and reduce or inhibit tumour growth. |
| Targets: | Histone deacetylase 1; Histone deacetylase 3; Histone deacetylase 2 |
| Inclusion Criteria: | Therapeutic strategy associated |
